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Abstract
Background: The production of cell-based cancer vaccines by gene vectors encoding proteins that
stimulate the immune system has advanced rapidly in model systems. We sought to develop non-viral
transfection methods that could transform patient tumor cells into cancer vaccines, paving the way for
rapid production of autologous cell-based vaccines.
Methods: As the extended culture and expansion of most patient tumor cells is not possible, we sought
to first evaluate a new technology that combines electroporation and chemical transfection in order to
determine if plasmid-based gene vectors could be instantaneously delivered to the nucleus, and to
determine if gene expression was possible in a cell-cycle independent manner. We tested cultured cell
lines, a primary murine tumor, and primary human leukemia cells from diagnostic work-up for transgene
expression, using both RFP and CD137L expression vectors.
Results:  Combined electroporation-transfection directly delivered plasmid DNA to the nucleus of
transfected cells, as demonstrated by confocal microscopy and real-time PCR analysis of isolated nuclei.
Expression of protein from plasmid vectors could be detected as early as two hours post transfection.
However, the kinetics of gene expression from plasmid-based vectors in tumor cell lines indicated that
optimal gene expression was still dependent on cell division. We then tested to see if pediatric acute
lymphocytic leukemia (ALL) would also display the rapid gene expression kinetics of tumor cells lines,
determining gene expression 24 hours after transfection. Six of 12 specimens showed greater than 17%
transgene expression, and all samples showed at least some transgene expression.
Conclusion: Given that transgene expression could be detected in a majority of primary tumor samples
analyzed within hours, direct electroporation-based transfection of primary leukemia holds the potential
to generate patient-specific cancer vaccines. Plasmid-based gene therapy represents a simple means to
generate cell-based cancer vaccines and does not require the extensive infrastructure of a virus-based
vector system.
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Background
The efficacy of cell-based tumor vaccines in murine mod-
els of malignancy is well established. Using tumor cells
lines transfected with soluble immune stimulatory mole-
cules such as IL-2 or IL-12, or cell surface co-stimulatory
antigens including CD80, and CD137L, or even alloge-
neic MHC results in profound immune activation [1-5].
The advantage of working in model systems is that unlim-
ited amounts of tumor are available to produce cell-based
vaccines. The ability to produce cell-based vaccines from
clinic-derived material, however, remains a challenge.
Cell-based vaccines from tumor-derived material have
been prepared and administered in either an allogeneic or
autologous fashion, recently reviewed by Mocellin, et al.
[1]. An allogeneic vaccine usually features the expansion
of a single tumor cell line that can grow well in culture,
genetic transduction by the desired vector, and prepara-
tion of large vaccine stocks that can be qualified for clini-
cal use. A vaccine for neuroblastoma featuring the
expression of both a cytokine and a chemokine transgene
(IL-2 and lymphotactin) by a single human neuroblast-
oma cell line is a recent example of this strategy [7]. The
disadvantage of a single cell line approach is that each
malignancy is to some degree unique, and perhaps the
most immunogenic antigens, or the most relevant ones
for a given patient, will fail to be expressed by the alloge-
neic vaccine.
Give these limitations, we propose that a cell-based vac-
cine could be produced in an autologous manner for
patients with a high disease burden, such as those who
present with significant bone marrow involvement. For
example, the large amount of tumor material typically
available from leukemia patients makes these cells acces-
sible for autologous patient-derived vaccine production.
A major hurdle to be overcome in using primary cells is
the need to culture tumor cells in vitro in order for trans-
duction or transfection procedures to be carried out. Most
malignancies will not survive in culture in large enough
numbers to be utilized. However, if the time required for
in vitro manipulation was minimized, for example to 8–
24 hours, patient-derived leukemia cells could be isolated
from blood or bone marrow, transfected, and then upon
irradiation used as a cell-based vaccine. Here we report the
application of a novel electroporation-based transfection
methodology that holds the potential to immediately
transform a patient tumor sample into a cell-based cancer
vaccine. This process, termed nucleofection, was pursued
in our laboratory because it is the most rapid method of
gene vector introduction available. We demonstrate that
even though delivery of a plasmid gene vector to the
nucleus is immediate, short-term culture is still required,
and that a single-round of cell division may be needed to
reach optimal gene expression levels. Importantly the
time for tumor vaccine preparation is now measured in
terms of hours instead of days. Our findings confirm stud-
ies carried out by Schakowski et al., where 3 samples from
acute myeloid leukemia (AML) patients were transfected
with a GFP expression vector [8]. The large degree of trans-
gene expression in the majority of patient-derived acute
lymphoblastic leukemia (ALL) specimens that we present
here suggests that a clinical trial using these procedures
should be pursued.
Methods
Cell lines
The mouse neuroblastoma cell line AGN2a, an aggressive
subclone of Neuro-2a, was cultured in Dulbecco's modi-
fied Eagle's medium (DMEM), 100 U/ml penicillin, 100
µg/ml streptomycin, 2 mM L-glutamine and 10% heat
inactivated fetal bovine serum (FBS), 1 mM MEM sodium
pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin,
0.01 M HEPES buffer, 2 mM L-glutamine, 0.05 M 2-mer-
captoethanol, and 0.069 M L-arginine HCl [4]. Primary
murine tumor was generated by subcutaneous injection of
1 × 106 cultured AGN2a cells into strain A/J mice (Jackson
Labs, Bar Harbor, ME). The human osteosarcoma cell line
U2OS, kindly provided by Dr. Kent Wilcox, Medical Col-
lege of Wisconsin, and the mouse squamous cell carci-
noma cell line SCCVII, kindly provided by Dr. Scott
Strome, Mayo Clinic, Rochester, MN, were cultured in
DMEM as above. Mouse primary tumors were processed
into single-cell suspensions by injection of 1–2 ml of 1
mg/ml collagenase D into the excised tumor mass (1 mg/
ml in 10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2) and incubated at 37°C for 45 min
followed by mechanical disruption through a sterile
screen. Tumor cells were washed in DMEM and PBS and
viable cells were separated by centrifugation over a Ficoll-
Paque™ (Amersham Biosciences, Piscataway, NJ) density
gradient.
Transfection of tumor cell lines
Tumor cells were transfected with either pcDNA3.1/
Hygro(-) (Invitrogen, Carlsbad, CA) or pDSRed2-C1 (BD
Biosciences, San Diego, CA) plasmid vectors using a cati-
onic lipid-based transfection methodology (Novafection,
VennNova, Inc., Pompano Beach, FL) or a proprietary
electroporation method (Nucleofection, Amaxa, Köln,
Germany). Cells were nucleofected with 0.5 µg plasmid
per 106 cells or lipid transfected with 0.5 µg plasmid and
2  µg of NovaFECTOR reagent per 106 cells. Similarly,
U2OS, SCCVII and AGN2a cells were nucleofected with
0.5 µg per 106 cells pDSRed2-C1. To determine expression
levels, cells were stained with 7AAD (BD Biosciences) and
the expression of red fluorescent protein (RFP) in live
gated cells was analyzed by flow cytometry (FACScan, Bec-
ton Dickinson, Franklin Lakes, NJ) at designated timeGenetic Vaccines and Therapy 2005, 3:4 http://www.gvt-journal.com/content/3/1/4
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points. U2OS and SCCVII cells were also nucleofected
with pCI-neo (Promega, Madison, WI) encoding CD137L
(4-1BBL) cDNA at a concentration of 1.5 µg per 106 cells
[5]. The CD137L transfected cells were stained with phy-
coerythrin (PE) conjugated mouse anti-human CDw137
Ligand (BD Biosciences Pharmingen, San Diego, CA).
Patient Samples
Patient leukemia and lymphoma samples were obtained
in accordance to the Helsinki Declaration from excess
bone marrow or peripheral blood specimens submitted to
the Cell Marker Lab, Children's Hospital of Wisconsin, for
routine leukemia screening. Studies involving these sam-
ples were approved by the Medical College of Wisconsin
and Children's Hospital of Wisconsin Institutional
Review Boards. Informed consent was obtained from the
parents or guardians of each child and each sample was
assigned a unique identifier number to ensure
confidentiality.
Transfection of primary acute lymphocytic leukemia cells
Leukocytes from bone marrow or peripheral blood
patient samples were separated by centrifugation over a
Ficoll-Paque™ density gradient. Cells were nucleofected
with 1 µg pDSRed2C-1 (red fluorescent protein, RFP,
expression vector) plasmid per 106 cells using a variety of
Amaxa solutions and program parameters, cultured in
RPMI-1640, 100 U/ml penicillin, 100 µg/ml streptomycin
and 10% heat inactivated FBS for 24 hours then analyzed
for RFP expression by flow cytometry (FACScan, Becton
Dickinson). FACS acquisition and analysis was done
using either propidium iodide (PI) or 7AAD to exclude
dead cells. The leukemic blast population phenotype was
determined by the flow cytometric and CD antigen
expression profile as compared to normal cell popula-
tions. Both CD45+ and CD45- leukemic blasts could be
gated when stained with anti-CD45 antibody and ana-
lyzed by flow cytometry for CD45 expression and side
scatter properties. All antibodies utilized were clinical
grade direct fluorochrome conjugates (Becton
Dickinson).
Confocal microscopy
U2OS cells were nucleofected with 3 µg fluorescein
labeled (Mirus Label  IT® Tracker, Madison, WI) pUC19
plasmid or pDSRed2C-1 plasmid per 106 cells. Immedi-
ately, or 3 days following nucleofection, cells were washed
in cDMEM and counted. Cells were fixed on a glass slide
with 3.7% buffered formalin, washed, permeabilized with
0.5% Triton X-100 (Surfact-amp, Pierce, Rockford, IL) and
washed again. Pearmeabilized cells were incubated with
2.4 nM TOTO3 (Molecular Probes, Eugene, OR) and
washed. Vectashield (Vector Laboratories, Inc., Burlin-
game, CA) was added to the cells prior to sealing with a
coverslip. Optical sectioning of cells was taken sequen-
tially using argon (488 nm excitation) and helium/neon
(633 nm excitation) lasers on a Leica SPT S2 confocal
microscope with a 100x oil immersion lens.
Quantitative real-time PCR
U2OS cells were nucleofected with 0.5 µg pDSRed2C-1
plasmid per 106 cells. Cells were harvested and used for
nuclear DNA isolation. Prior to DNA isolation, nuclei
were washed in PBS and incubated with 0.5U DNase I
(Ambion, Austin, TX) at 37° for 10 min and washed again
twice in PBS. Nuclear DNA was isolated (Nuclei EZ prep,
Sigma, Saint Louis, MO) from transfected cells at desig-
nated time-points. The plasmid encoded neomycin phos-
photransferase gene (neo) was amplified with primers and
TaqMan hydrolysis probe as described by Sanburn, et al.
[9]. Nuclear DNA from each of three experimental and
three parallel control samples (U2OS cells Nucleofected
without plasmid) was amplified in triplicate in an Opti-
con™ 2 Cycler (MJ Research™, Inc., Waltham, MA) with
the following cycling protocol: 50°C 2 min, 95°C 10 min,
with 40 cycles of 95°C for 15 sec., and 62°C for 1 min. To
normalize the number of cells/nuclei, human RNase P
was amplified using the TaqMan® RNase P reagents kit
(Applied Biosystems, Foster City, CA), or for mouse cells,
mouse Apo B was amplified using the primers 5' CACGT-
GGGCTCCAGCATT 3'and 5' TCACCAGTCATTTCT-
GCCTTTG 3' and the TaqMan hydrolysis probe 5'(FAM)
CCAATGGTCGGGCACTGCTCAATA (TAMRA) 3' (cour-
tesy Renee Horner, qpcrlistserver, yahoo groups,
yahoo.com). The neo gene copy number per cell was deter-
mined using a plasmid-based standard curve.
Analysis of cell division
Cells were suspended in PBS and incubated with CFDA SE
(5-(and -6)-carboxyfluorescein diacetate succinimidyl
ester, CFSE (Molecular Probes, Eugene, OR) at a final con-
centration of 0.35 µM per 4 × 106 cells, incubated for 10
min at 37°C, and washed x3 in DMEM, 10% FBS. CFSE
expression was analyzed by flow cytometry to assess cell
division.
Cell cycle blockade
At 50–60% confluency, 0.6 mM mimosine (Sigma, Saint
Louis, MO) was added to U2OS cells (2). Both U2OS and
U2OS cells treated with mimosine were incubated at
37°C for 48 hours at which time the cells were harvested,
counted and nucleofected with 1.5 µg per 106 cells pCI-
neo vector encoding human 4IBBL (CD137L) cDNA [5].
As a control, cells were also nucleofected without plasmid.
Four hours post-nucleofection cells were harvested,
counted, stained with phycoerytherin (PE) labeled anti-
human CD137L (BD Biosciences) and 7AAD (BD Bio-
sciences), and analyzed for CD137L-expression by flow
cytometry. To determine DNA content prior to nucleofec-
tion, cells were washed in phosphate buffered salineGenetic Vaccines and Therapy 2005, 3:4 http://www.gvt-journal.com/content/3/1/4
Page 4 of 13
(page number not for citation purposes)
(PBS), fixed with 4% paraformaldehyde, washed again in
PBS, and 1 µl propidium iodide (BD Bioscience) at 50 ug/
ml was added. The propidium iodide labeled cells were
then analyzed by flow cytometry [11].
Results
Optimization of Transfection by Electroporation
To determine differences in the kinetics and strength of
expression of a transfected reporter gene using either an
electroporation method (nucleofection) or a cationic
liposome-based methodology (novafection), U2OS
human osteosarcoma cells were transfected with 0.5 µg
pDSRed2C-1 (RFP) plasmid per 106 cells, and RFP protein
expression measured over time by flow cytometry. Fol-
lowing nucleofection, RFP was expressed as early as 4
hours in U2OS cells, Figure 1A. By 12 hours, 60% of the
nucleofected cells expressed RFP. When this rate was
adjusted for the cell death associated with nucleofection,
the transfection rate dropped to 18% of the total cells ini-
tially transfected now expressing RFP at 12 hours. On day
3, when the percent viability of the nucleofected cells
returned to 100%, the transfection rates no longer needed
correction and the reported rates are identical. This expres-
sion was maintained for several days and gradually dimin-
ished until day 14 when expression could no longer be
detected. In contrast, using novafection, RFP expression
required 12 hours of culture (as opposed to 4 hours for
nucleofection) and did not approach peak expression lev-
els until day 1, Figure 1B. The efficiency of transfection
was determined by using identical amounts of plasmid
gene vector in each method. Upon comparison of RFP
expression levels at day 1, the superiority of electropora-
tion-based transfection was evident. In the viable fraction
of nucleofected cells, 60% of these cells expressed RFP at
24 hours, as opposed to 15% of the novafected cells. Even
when corrected for cells lost to electroporation-associated
cell death, the nucleofection expression rate is 26%. As a
control, cells were also nucleofected with a non-RFP
expressing plasmid, pcDNA3.1/Hygro(-), and the mini-
mal autofluoresence of transfected cells (less than 2%)
subtracted from the reported expression levels. The RFP
expression levels in cells transfected with the liposome-
based reagent could be increased by increasing the
amount of plasmid DNA, therefore these comparisons are
relative and not maximized for each method (not shown).
We then tested a primary mouse-derived neuroblastoma
mass for the ability to be transfected by these methodolo-
gies. AGN2a tumor cells were injected subcutaneously
into host strain mice, A/J, and the resulting subcutaneous
tumor cell mass was excised, processed into a single-cell
suspension, transfected with 0.5 µg pDSRed2C-1 (RFP)
plasmid per 106 cells, and RFP expression over time meas-
ured by flow cytometry. Nucleofected primary murine
tumor cells began to express RFP earlier than novafected
cells (5 hr versus 1 day) and expression levels peaked at
day 2 in viable nucleofected cells and day 4 in novafected
cells, Figure 2. This later peak is likely due to the longer
duration of transgene expression in novafected cells. Both
the kinetics and total RFP expression levels differed for the
human U2OS cell line, Figure 1, and the primary mouse-
derived tumor, AGN2a, Figure 2. The nucleofection rates
were not as high for the nucleofected primary tumor,
while the novafection rate improved. These are vastly dif-
ferent systems and the rapid cell division rate of the cul-
tured U2OS, Figure 3, as opposed to uncultured tumor
that was excised, processed into a single cell solution and
then transfected, may partially explain this result.
The primary limitation of electroporation-based transfec-
tion is cell death. Preliminary experiments confirmed that
increasing the strength of the electric field corresponded
to both a higher transfection rate, and increased cell
death. The nucleofection setting that we found optimal
resulted in 70% cell death, Figure 1A. Cell numbers grad-
ually recovered post-nucleofection, beginning at 24
hours. In contrast, there was no decrease in cell number
following novafection, Figure 1B.
Delivery of plasmid DNA to the nucleus by electroporation 
is rapid and short-lived
The inability to culture most primary human tumors led
us to search for methods of transfection that would
require minimal culture and processing time while allow-
ing for efficient gene transfection. Given the rapid kinetics
of expression using nucleofection, we sought to determine
if this was due to direct delivery of plasmid DNA in to the
nucleus. Confocal microscopy was used to visualize indi-
vidual z-plane sections that represent internal nuclear lay-
ers of U2OS cells that had been nucleofected with 3 µg
FITC-labeled pUC19 plasmid per 106 cells, immediately
cytospun onto glass slides, and then prepared for micros-
copy. The nuclear and cytoplasmic boundaries of nucleo-
fected cells were visualized by phase contrast microscopy,
Figure 3A, panel b, or by staining with the nuclear dye
TOTO3, Figure 3A, panel c. The nuclei are stained dark
blue, with a lighter blue staining in the cytoplasmic com-
partment. The plasmid-associated fluorescein signal was
present in both the cytoplasmic and nuclear compart-
ments immediately following nucleofection, Figure 3A,
panel d. Visual inspection reveals that most cells con-
tained nuclear plasmid, Figure 3A, d (an overlay of the
plasmid signal with the TOTO3 stain).
Using the same technique, we then sought to determine
how long after nucleofection the plasmid vector remained
in the nucleus. Three days after nucleofection of U2OS
cells with 3 µg FITC-labeled pDSRed2C-1 (RFP) plasmid
per 106 cells, the presence of plasmid vector DNA, was
greatly diminished, Figure 3B, panel a. The presence ofGenetic Vaccines and Therapy 2005, 3:4 http://www.gvt-journal.com/content/3/1/4
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Kinetics of transgene expression in electroporated and cationic lipid transfected U2OS cells Figure 1
Kinetics of transgene expression in electroporated and cationic lipid transfected U2OS cells. (A) RFP expression over time in 
cultured U2OS cells when nucleofected with pDSRed2C-1 (RFP) plasmid. Black bars represent the percent cells expressing 
RFP corrected for the total number of cells transfected and gray bars represent the percent of viable cells expressing RFP. (B) 
RFP expression over time in cultured U2OS cells when novafected with pDSRed2C-1 (RFP) plasmid. Since there is no cell 
death associated with novafection, the gray and black bars both represent the percent cells expressing RFP from the total 
number of cells transfected. Autofluorescence (always <2%) detected from cells nucleofected or novafected with pcDNAHy-
gro(-) control plasmid was subtracted from the experimental values. The black line in both A and B represents average cell 
number at each time point. All experiments were done in triplicate with the standard deviation indicated by the error bars.
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plasmid vector DNA, as detected by FITC fluorescence,
was seen in a small minority of cells, and when present on
day 3 it appeared to associate more with a punctate fluo-
rescence in the cytoplasm, Figure 3B, a and d. Despite the
loss of plasmid vector from the nucleus, intense red fluo-
rescence was seen in many of the cells at this time, indicat-
ing the continued presence of red fluorescent protein,
Figure 3B, panels b and d.
To further confirm the presence of plasmid in the nucleus,
the copy number of plasmid vector per cell was calculated
by real-time PCR amplification of the pDSRed2C-1
encoded neomycin phosphotransferase gene (neo). U2OS
cells were nucleofected with 0.5 µg pDSRed2C-1 per 106
cells and immediately, or at day 3, nuclear DNA was iso-
lated from the nuclear fraction of cell lysates and PCR
amplified using neo primers and a neo-specific TaqMan
probe. The total number of plasmid neo copies was calcu-
lated based on comparison to a standard curve generated
with the same plasmid vector. The number of cells (or
nuclei) analyzed was determined using a standard curve
calibrated to genomic DNA mass and signal from the sin-
gle copy gene RNAseP. Nuclei were purified on a sucrose
cushion, washed with PBS, digested with DNAse in order
to remove contaminating cytoplasmic plasmid DNA, and
total DNA extracted. Immediately following nucleofec-
tion, there were 200 to 400 copies of plasmid per cell, Fig-
ure 3C. In agreement with microscopy data, copy number
in U2OS cell nuclei decreased to 50 copies or less per cell
by day 3 post-nucleofection, Figure 3D. Immediate local-
ization of plasmid to the nucleus following nucleofection
was also observed by real-time PCR in the AGN2a and
SCCVII cell lines (data not shown).
Delivery of plasmid gene vectors to the nucleus requires 
cell division for optimal gene expression
The ideal cell-based cancer vaccine would allow recom-
binant gene expression in primary human tumor cells.
The bottleneck is that primary human tumors do not grow
and divide efficiently in culture. Therefore, it was essential
to evaluate the association between cell division and
expression of nucleofected genes. To determine the
Kinetics of transgene expression in electroporated and cationic liposome transfected mouse primary tumor Figure 2
Kinetics of transgene expression in electroporated and cationic liposome transfected mouse primary tumor. The percent 
AGN2a mouse primary tumor cells expressing RFP in nucleofected (black bars) and novafected (gray bars) cells is shown. 
Autofluorescence detected from cells nucleofected or novafected with pcDNAHygro(-) control plasmid was subtracted from 
the experimental values. All experiments were done in triplicate with the standard deviation indicated by the error bars.
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pattern of cell division rates in nucleofected tumor cell
lines (U2OS, AGN2a and SCCVII), cultured tumor cell
lines were incubated with carboxyfluorescein diacetate
succinimidyl ester (CFSE). The intensity of CFSE fluores-
cence was analyzed by flow cytometry every two hours for
10 hours and then daily for 3 days after nucleofection, Fig-
ure 4A–C. According to the decrease in CFSE fluorescence
intensity with each cell division (leftward shift of peaks),
the U2OS cells underwent about 3 cell divisions in the
first 10 hours post-nucleofection, whereas, the AGN2a
and SCCVII cells divided approximately once in the first
10 hours post-nucleofection. CFSE stained cells were also
nucleofected with RFP-encoding plasmid and there was
no difference in the CFSE fluorescent pattern by flow
Confocal images of FITC-labeled plasmid in U2OS cells immediately and 3 days following nucleofection Figure 3
Confocal images of FITC-labeled plasmid in U2OS cells immediately and 3 days following nucleofection. A) Confocal images 
captured immediately following nucleofection: a) fluorescence of FITC-labeled pUC19 plasmid, b) phase contrast image, c) 
TOTO3 stained nuclei (dark blue), d) overlay of the images in (a) and (c) showing FITC-labeled plasmid in the nucleus. B) Con-
focal images captured 3 days following nucleofection: a) fluorescence of FITC-labeled pDSRed2C-1 plasmid, b) fluorescence 
from expression of RFP encoded on the FITC-labeled pDSRed2C-1 plasmid, c) TOTO3 stained nuclei, d) an overlay of the 
images in a, b and c showing FITC-labeled plasmid, expression of RFP and nuclear localization. C) Average number of plasmid 
copies per cell as determined by real-time PCR of the plasmid encoded neo gene from nuclear DNA harvested immediately fol-
lowing nucleofection. D) Plasmid neo copies amplified from nuclear DNA harvested 3 days following nucleofection. In both C 
and D the gray bars represent neo amplification from U2OS cells nucleofected with 0.5 µg pDSRed2C-1 per 106 cells and the 
black bars represent neo amplification from non-nucleofected U2OS cells. Nuclear DNA was harvested and amplified from 3 
separate samples, error bars indicate the standard deviation from the average of triplicate samples.
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cytometry in the nucleofected versus non-nucleofected
cells (data not shown). As demonstrated previously, it was
the rapidly dividing U2OS cells that exhibited transgene
expression at 4 hours (20% of the viable expressed RFP),
while RFP could not be detected in the slower dividing
AGN2a and SCCVII until 12 hours post-nucleofection,
Figure 4D.
Cell division and gene expression in U2OS, AGN2a and SCCVII cells Figure 4
Cell division and gene expression in U2OS, AGN2a and SCCVII cells. Tumor cells were labeled with CFSE to detect changes in 
fluorescence that occur with cell division post-nucloefection. (A) U2OS, (B) cultured AGN2a, (C) SCCVII cells were analyzed 
for CFSE fluorescence by flow cytometry immediately following nucleofection or cultured up to 3 days following nucleofection. 
The solid gray peak (far left of each panel) represents unstained cells. Peaks decreasing in fluorescence (right to left) indicate 
the loss of CFSE fluorescence over time as cells divide. Cells were analyzed at hour 2, 4, 6, 8, 10, day 1, day 2, and day 3. Only 
U2OS showed peaks indicating decrease in fluorescence prior to day one: at hour 2, and hours 4–10. D) In parallel experi-
ments, the average percent of cells expressing RFP from 3 separate experiments at the indicated time points following nucleo-
fection was determined in U2OS (■ ), SCCVII (▲ ) and AGN2a (◆ ) cell lines by flow cytometry. E) Average percentage of cells 
expressing CD137L at time 0, 2 hours, and 6 hours post-Nucleofection in U2OS and SCCVII cells. The error bars represent 
the standard deviation from 3 experiments. F) Average viable cell number of U2OS, SCCVII and AGN2a tumor cells post-
nucleofection from 3 separate experiments, expressed as a percentage of the number of cells originally nucleofected.
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To further explore this finding, we used an alternate plas-
mid-encoded transgene and compared the kinetics of
expression in rapidly and slower dividing cell lines. Our
laboratory has produced a number of immune co-stimu-
latory expression vectors, and we chose a human CD137L
(4IBBL) expression vector for further study. Expression of
this cell-surface antigen can be directly measured by flow
cytometry using a labeled CD137L-specific antibody. One
of our concerns with using RFP was that the DsRed2 pro-
tein we utilized requires approximately 6 hours to reach
full fluorescence intensity due to a requirement for intrac-
ellular oxidation [12]. Therefore a CD137L-encoding
plasmid, 1.5 µg per 106 cells, was nucleofected into the
U2OS and SCCVII cells and expression compared. In the
rapidly dividing U2OS, 40% of the cells expressed
CD137L as early as 2 hours post-nucleofection. At 6 hours
post-nucleofection, 80% of the U2OS cells expressed
CD137L, Figure 4E. In contrast, only 10% of SCCVII cells
expressed CD137L at 6 hours post-nucleofection. The
nucleofection process also induced significant cell death,
demonstrating that cell death was not an RFP-associated
phenomenon, Figure 4F. All cells experienced 60 to 80%
cell death upon nucleofection, however the SCCVII cells
recovered much more rapidly than either the rapidly
dividing U2OS cells or the less rapidly dividing AGN2a
cells, indicating that factors other than cell division are
involved in cellular recovery from the electroporation and
transfection processes.
To directly assess the need for cell division, U2OS cells
were incubated with 0.6mM mimosine, which blocks cell
cycle progression, and CD137L expression of nucleo-
fected cells compared to non-treated controls, Figure 5A.
In non-mimosine treated U2OS cells, approximately 20%
of cells expressed CD137L at 4 hours post-nucleofection.
In contrast, less than 4% of mimosine treated cells
expressed CD137L at 4 hours post-nucleofection. To
assure that cell cycle block occurred in mimosine treated
cells, cell cycle status was determined by propidium
iodide staining. The majority of mimosine treated cells
were in G1/G0 while the mimosine untreated cells had a
greater proportion of cells in S, and G2/M phases of the
cell cycle, Figure 5B. This finding indicates that cell cycle
progression enhances transgene expression by nucleofec-
tion. This finding was unexpected as it implies that other
mechanisms are at work besides the delivery of plasmid
DNA to the nucleus.
Application of electroporation-based transfection to 
human leukemias
To assess the ability of electroporation-based transfection
to be utilized in the production of autologous tumor vac-
cines for patients, we first determined the optimal electro-
transduction parameters. Fresh primary leukemia cells
from 6 patient samples were nucleofected with 1 µg of
pDSRed2C-1 plasmid per 106 cells, using three different
Amaxa solutions (R, T, V) and several different electro-
transduction programs (T20, U15, T17, T27, S04, O17,
T16, T01, and O17). The expression of RFP protein was
determined by flow cytometry 24 hours post-nucleofec-
tion. There was a wide range of RFP expression depending
on the electroporation conditions, Table 1. Amaxa solu-
tion R with program T20 and solution T in combination
with program U15 consistently provided the highest
expression of RFP protein. The highest expression level
seen was 62%, (sample 4 PB) and the lowest expression
was 1.8% (sample 12 BM). The RFP expression of 12 total
samples collected using solution R and program T20,
along with available diagnostic phenotypic information,
is presented in Table 2. The R/T20 settings were chosen
based on a slightly better viability profile than the T/U15.
Greater than 5% expression was seen in 9 of 12 samples
and greater than 20% expression was seen in 5 of 12 sam-
ples. These patient leukemias were extensively character-
ized for standard childhood leukemia markers, and no
phenotype was clearly associated with the ability to be
transfected using the parameters we established. Although
not reported, the number of leukemic cells obtained per
patient was variable- as the samples obtained for this
study were essentially diagnostic remains that were to be
discarded. For two of the samples (5 and 6) we had both
peripheral blood and bone marrow-derived matched
samples. In both cases the peripheral blood cells showed
a higher transfection rate. Our certainty that the trans-
fected cells analyzed were the leukemia cells comes from
the clinical diagnostic experience of the Cell Marker Lab-
oratory of the Children's Hospital of Wisconsin, where the
identical procedures used for clinical diagnosis of malig-
nancy were used to analyze the nucleofected samples. The
majority of the samples we analyzed were bone marrow
aspirates. In patients with advanced disease, autologous
bone marrow may prove to be both an accessible and
abundant source of tumor cells that can be modified by
plasmid-based gene vectors to produce cell-based
vaccines.
Discussion
Cell-based autologous cancer vaccines hold great promise
in the effort to shift the adaptive immune system from
ignorance or anergy toward cell-mediated immune recog-
nition of cancer. The generation of a Th1-type immune
response with cell-based vaccines, and the resultant CTL-
mediated killing of tumor, have offered the most effective
anti-tumor responses in pre-clinical models, and also ini-
tiated clinical responses, as reviewed by Nitti et al., [13].
Ex vivo introduction of gene vectors encoding immune
activating signals (such as co-stimulatory antigens,
cytokines and adhesion molecules) into tumor cells with
subsequent re-introduction of irradiated modified tumor
cells into patients is currently being pursued with the aimGenetic Vaccines and Therapy 2005, 3:4 http://www.gvt-journal.com/content/3/1/4
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Impact of cell cycle inhibition on gene vector expression Figure 5
Impact of cell cycle inhibition on gene vector expression. A) The average percentage of U2OS cells expressing vector-encoded 
CD137L 4 hours following nucleofection. The black bar represents cells nucleofected without plasmid, stippled bar represents 
untreated cells, and the gray bar represents mimosine treated cells. The error bars show the standard deviation from 3 sepa-
rate experiments. B) Flow cytometric profile of propidium iodide stained mimosine treated U2OS cells (solid gray) and mimo-
sine untreated U2OS cells (black line) prior to nucleofection of CD137L.
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of initiating a clinically-relevant immune response against
tumor [14,15]. Because this type of therapy involves cell
processing, culture procedures, as well as genetic transfer,
any steps that streamline the process will make a signifi-
cant contribution toward tumor vaccine development.
Newer generation transfection procedures based on elec-
troporation or branched polyethyleneamine (PEI) have
been reported to be independent of cell cycle effects [14].
Nevertheless, we found that cell cycle progression does
enhance transgene expression and that certain tumor cell
lines (such as U2OS) thought to be highly "transfectable"
may be highly amenable to vector-derived transgene
expression precisely because they have rapid rates of cell
division. Most reports do not analyze transgene expres-
sion at the early times (2–8 hours) we report here, and
unless proven otherwise, the contribution of cell cycle
progression within the first 8 hours of transfection cannot
be excluded. We examined this question in detail because
our goal is to transfect primary human leukemias that do
not persist in tissue culture and thus have limited in vitro
proliferative capacity.
Having thus defined the problem, we examined in detail
a transfection procedure that appears to be the most rapid.
Nucleofection delivers plasmid vector DNA in to the
nucleus immediately, Figure 3. However, as we demon-
strate here, nucleofection still benefits from cell cycle pro-
gression and cell division, Figures 4,5. Using
nucleofection we found that tumor cells harvested directly
from a mouse bearing the AGN2a neuroblastoma could
be nucleofected with high efficiency. Thus, the process of
tumor disaggregation and processing did not render the
neuroblastoma cells we studied resistant to nucleofection.
Confident of these results, we initiated analysis of primary
human tumors.
The tumor samples we analyzed were from patients
undergoing diagnosis for suspected childhood leukemia.
If samples from blood or bone marrow remained after
diagnostic procedures were completed, they were then
tested for the ability to be nucleofected. Nine of 12 speci-
mens showed greater than 5% transgene expression, and
half of these showed greater than 17% expression, Table
2. This means that for the majority of the patients we
tested, nucleofection with transgenes that encode either
immune co-stimulatory molecules or cytokines may be
feasible. We did not analyze gene expression in
nucleofected ALL specimens over time, as our long-term
goal is to transfect and then use these cells as experimental
vaccines soon thereafter. Studies with other cultured
tumor cell lines in our lab have shown that transgene
expression rarely persists beyond 9 days, as nucleofected
plasmid vectors do not integrate into the genome. While
clinical samples could be frozen, thawed, cultured over-
night, and then nucleofected, the viability of the frozen
and thawed clinical samples was low, between 10–25%
(not shown). We propose that the highest nucleofection
rates are likely to be seen using fresh leukemic cells, and
that viability upon thawing may not be critical as cells will
be irradiated prior to use as a vaccine. Future studies will
be carried out to address this issue. Our report also high-
lights that the nucleofection of primary ALL was quite var-
iable. Reasons for this could be due to a specific
phenotype that could be identified by expression
profiling. Building upon our in vitro data it may be the
ability of one clinical sample to undergo cell division or
even limited expansion in culture over another during the
overnight culture period following nucleofection may
allow for better transgene expression. Thus, inclusion of
growth factors or cytokines may increase nucleofection
rates above those we report here.
Table 1: Comparison of nucleofection parameters in ALL patient samples. Nucleofection using an RFP expression vector was carried 
out using 6 different patient samples (patients 4,13,8,11,19,12) from one of two potential tissue sources, PB, peripheral blood, or BM, 
bone marrow. 1No NF, not nucleofected autofluorescence control. 2Nucleofection was carried out with one of three solutions R, T, or 
V, and the following electrical settings on the Amaxa nucleofection device: T20, U15, T17, T27, S04, O17, T16, T01, O17. 3The table 
lists the percentage of viable cells expressing the plasmid-encoded RFP at 24 hours post-nucleofection.
Electroporation Parameters
Patient 
Samples
No NF1 R2/T20 T/U15 R/T17 R/T27 T/S04 T/O17 R/T16 V/T01 V/O17
4 PB 30.1 62.3 61.5 56.8 52.9 52.5 46.2 46.1 40.5 20.9
13 BM 1.0 45.0 45.6 42.9 40.2 32.4 36.1 38.5 21.3 36.1
8 PB 1.0 9.2 10.9 9.3 6.7 8.2 5.6 6.4 6.1 3.7
11 BM 1.2 17.1 25.2 13.2 13.4 9.5 5.7 10.0 5.7 7.1
10 BM 0.1 8.0 10.0 4.6 4.5 2.3 2.0 3.9 2.0 0.9
12 BM 1.3 2.9 3.6 2.4 2.3 2.6 3.5 1.8 2.1 3.6Genetic Vaccines and Therapy 2005, 3:4 http://www.gvt-journal.com/content/3/1/4
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Conclusion
The process of nucloefection delivers plasmid DNA
directly to the nucleus. Even though delivery to the
nucleus is thought to circumvent dependence on cell divi-
sion, we found that the highest and earliest levels of trans-
gene expression from plasmid-based vectors occurred in
rapidly dividing cells. We were also able to demonstrate
that primary acute lymphocytic leukemia cells (ALL) from
pediatric patients could also be nucleofected with plas-
mid-based vectors, thus opening the door to patient-spe-
cific cell manipulation. In light of the laboratory studies
we present, transfection rates of clinical samples may be
increased even further if some degree of cell division
could be induced during the in vitro culture of these spec-
imens. Even though this culture time is less than 24 hours,
a single cell division could potently increase transgene
expression levels, and thus immunogenicity of the vaccine
preparation. Future work will include analysis of the cor-
relation between the ability to be nucleofected, markers of
cell cycle progression, and the induction of cell cycle pro-
gression post-nucleofection.
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